Physician profile
Young Jun Kim
NPI 1417732546
$3,262.86
in general payments reported to CMS, 2019-2025
24 companies · $1,916 in 2025
The $1,916 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $177 · 2024: $1,170 · 2025: $1,916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,243 · Education: $19.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,242.97 |
| Education | $19.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $652.11 | 2024-2025 | |
| Madrigal Pharmaceuticals | $492.53 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $403.40 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $322.76 | 2024-2025 | Xifaxan, Relistor |
| Janssen Biotech, INC. | $217.40 | 2025 | Tremfya |
| Ardelyx, INC. | $210.73 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $185.01 | 2024-2025 | |
| Pfizer INC. | $126.27 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $119.74 | 2023-2025 | Dupixent |
| Alnylam Pharmaceuticals INC. | $70.47 | 2024-2025 | Givlaari |
| Mallinckrodt Hospital Products INC. | $62.09 | 2024 | Terlivaz |
| Organon LLC | $51.50 | 2024-2025 | Renflexis, Hadlima |
| Phathom Pharmaceuticals, INC. | $47.61 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $42.95 | 2024 | Omvoh |
| Gilead Sciences, INC. | $37.25 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $34.05 | 2023-2024 | Ocaliva |
| Invivyd INC | $32.52 | 2025 | Pemgarda |
| Evoke Pharma, INC. | $29.21 | 2025 | |
| Aimmune Therapeutics, INC. | $24.90 | 2025 | Vowst |
| Amgen INC. | $24.07 | 2025 | Uplizna |
| Fresenius Kabi USA, LLC | $22.09 | 2024 | Idacio |
| Celgene Corporation | $20.49 | 2023 | Zeposia |
| Celltrion USA INC. | $19.89 | 2024 | Zymfentra |
| Ironwood Pharmaceuticals, INC | $13.82 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Young Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.